Volatiles and trace element contents in melt inclusions from the zoned Green Tuff ignimbrite (Pantelleria, Sicily): petrological inferences.

The island of Pantelleria is one of the best known localities of bimodal mafic-felsic magmatism (alkali basalt and trachyte-pantellerite). Among the felsic rocks, the coexistence in a single eruption of products of both trachyte and pantellerite compositions is limited to few occurrences, the Green Tuff (GT) ignimbrite being one of these. The GT is compositionally zoned from pantellerite (70.1 wt% SiO2, mol Na+K/Al = 1.86, 1871 ppm Zr) at the base to crystal-rich (\u3e30 vol%) comenditic trachyte (63.4 wt% SiO2, mol Na+K/Al = 1.10, 265 ppm Zr) at the top, although the pantellertic compositions dominate the erupted volume. We present here new data on melt inclusions (MIs) from the pantellerite portions of the GT eruption and, most importantly, from the trachyte member, which have not been studied in-situ by previous work focused on the GT. We document the first occurrence of trachytic melt inclusions in the late-erupted member, whose importance resides in the fact that trachytes were known mostly as crystal-rich lavas or ignimbrites, all variably affected by crystal accumulation. Besides the obvious inferences on the interplay between parental-derivative magmas, this evidence adds also some helpful elements in understanding zoning of silicic and peralkaline (i.e. low-viscosity) magma chambers. Trace elements compositions of MIs reveal that trachyte melts are of two types: (i) a low-Ba, directly descending from basaltic melts by 60-70 % of fractional crystallisation, and (ii) a high-Ba that might be affected by processes of feldspar dissolution and entrainment of the resulting small-scale melts in some MIs. MIs hosted in the deep-seated trachyte body are H2O-poor (≤ 1.2 wt %) with respect to the early erupted (and shallower) pantellerite magma (≤ 4.2 wt %), raising the possibility that either trachyte magma was H2O-undesaturated, or clinopyroxene hosted melt inclusions which suffered consistent H2O loss

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)